查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2138123

疫苗研發和冷鏈物流市場：預測（至2034年）－按價值鏈階段、疫苗類型、冷鏈組成部分、運輸方式、最終用戶和地區分類的全球分析

Vaccine Development & Cold Chain Logistics Market Forecasts to 2034 - Global Analysis By Value Chain Stage, Vaccine Type, Cold Chain Component, Mode of Transport, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球疫苗研發和冷鏈物流市場規模將達到 187 億美元，並在預測期內以 8.4% 的複合年成長率成長，到 2034 年將達到 357 億美元。

疫苗研發和冷鏈物流在將安全有效的疫苗從研發機構送達患者手中方面發揮著至關重要的作用。研發過程包括藥物發現、實驗室研究、臨床試驗、法規核准、生產和商業化。冷鏈系統透過在儲存和運輸過程中將疫苗保持在指定的溫度範圍內，有助於維持疫苗的有效性。先進的冷凍技術、溫度感測器、監控設備、保溫包裝和數位化追蹤解決方案提高了配送效率。可靠的冷鏈網路對於提高偏遠地區和醫療服務匱乏市場的疫苗接種率尤其重要。

據聯合國兒童基金會稱，到2024年，將向99個國家供應27.87億劑疫苗，足以覆蓋全球約45%的五歲以下兒童。這顯示全球疫苗採購和分發活動規模龐大，對冷鏈物流的需求也十分迫切。

擴大全球疫苗接種計劃並提高免疫接種率

免疫接種舉措的擴展正在推動疫苗研發和冷鏈物流的需求成長。隨著國家免疫規劃和國際衛生行動覆蓋更多人群和更廣闊的地域，對疫苗生產、受控儲存、冷藏運輸和高效配送的需求持續成長。免疫接種率的提高凸顯了在農村地區和低度開發地區提供可靠的「最後一公里」物流的重要性。這促使人們增加對冷藏保管基礎設施、溫度控制技術、保溫容器、監控設備以及疫苗配送專用運輸解決方案的投資。

溫度控制基礎設施高成本

開發和維護溫控基礎設施的高昂成本可能會阻礙市場擴張。冷鏈運作需要對專用冷凍設備、冷凍庫、冷藏運輸、保溫包裝、監控技術、備用電源和受控儲存設施進行大量投資。持續的能源消耗、維護、校準和設備更換進一步增加了營運成本。這些財務負擔對於在開發中國家或偏遠地區營運的醫療保健和物流公司而言尤其嚴峻，可能會阻礙冷鏈的擴展並降低疫苗配送效率。

擴大新興市場疫苗的取得途徑

在發展中地區和醫療服務不足的地區提高疫苗供應，為疫苗研發企業和冷鏈物流公司帶來了新的成長機會。不斷上漲的醫療成本、免疫宣傳活動以及不斷擴大的預防性醫療項目，都催生了對可靠的溫控儲存和運輸的需求。企業可以透過建造本地冷藏設施、部署太陽能冷鏈設備、提供保溫運輸方式和數位化溫度監控技術來掌握這項機會。提升最後一公里配送能力，能夠更有效地為偏遠地區的居民提供支援。這些投資將拓展物流網路，並有助於在新興醫療市場擴大疫苗的可近性。

供應鏈中斷與基礎設施脆弱性

全球疫苗供應鏈仍然容易受到干擾，這些干擾可能會影響冷藏保管和配送作業。極端天氣、物流延誤、地緣政治不穩定、電力短缺、設備故障和基礎設施脆弱等因素都會阻礙溫控運輸。這些挑戰可能導致交付延遲、產品損失和疫苗供不應求，尤其是在脆弱地區。對穩定電力供應、專用冷藏設施和協調物流的依賴進一步增加了營運風險。企業和醫療系統可以透過建立備用設施、確保替代運輸路線、制定緊急時應對計畫以及擴大區域儲存設施來降低這些威脅。

新型冠狀病毒（COVID-19）的影響：

新冠疫情迅速擴大了全球疫苗的研發、測試、生產和接種工作，徹底改變了疫苗開發和冷鏈物流格局。如此大規模的部署顯著增加了對冷藏保管和溫控運輸的需求。然而，旅行限制、邊境關閉、人手不足和基礎設施不足等問題在多個市場造成了供應鏈挑戰。為此，各國政府和醫療機構加大了對冷藏保管設施、溫度監控、專用包裝和配送系統的投資。此次危機凸顯了加強冷鏈韌性、提高數位化透明度、做好緊急準備以及最佳化物流營運的必要性。

在預測期內，分銷和冷鏈物流行業預計將佔據最大的市場佔有率。

預計在預測期內，分銷和冷鏈物流領域將佔據最大的市場佔有率。這是因為疫苗從生產地到接種點的整個運輸過程中都需要溫度控制。該領域涵蓋冷藏運輸、冷藏倉儲、溫控包裝、庫存管理、監控技術以及最後一公里配送。營運需要製藥企業、物流公司、醫療機構和接種點之間的密切協調，使其成為全球整體疫苗供應鏈的關鍵環節。

預計疫苗中心產業在預測期內將呈現最高的複合年成長率。

在整個預測期內，鑑於疫苗接種中心在社區免疫接種中的重要性持續提升，預計該行業將呈現最高的成長率。對免疫接種可近性的日益重視、大規模免疫接種舉措的開展以及分散式醫療服務的進步，都在強化該行業在疫苗分發網路中的作用。此外，透過實施數位化庫存管理和先進的溫度控制解決方案，營運效率也在不斷提高。這些進步使疫苗接種中心能夠支持擴大疫苗供應，並在社區層面實現更有效率的免疫接種。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療保健體系、強大的製藥產業和完善的疫苗分銷基礎設施。該地區擁有廣泛的疫苗研發、生產、冷藏保管、運輸和分銷活動。領先的製藥企業、醫療機構、疫苗接種設施和專業物流供應商構成了一個完整的生態系統，支撐著該地區在疫苗供應和分銷方面發揮的關鍵作用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於該地區疫苗接種工作、醫療基礎設施和疫苗生產的持續擴張。對可靠的儲存、運輸、監測和配送的需求不斷成長，推動了整個供應鏈的改善。新疫苗的推出進一步提升了全部區域對冷鏈的需求。各國政府、國際組織和醫療機構對物流基礎設施、數位追蹤和溫控系統的投資，正在增強疫苗分發能力，並支持市場擴張。

免費客製化服務：

訂閱本報告的用戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣量身定做的主要國家/地區的市場估算、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 成長要素、挑戰與機遇
  • 競爭格局概述
  • 戰略考慮和建議

第2章：分析框架

  • 分析的目標和範圍
  • 相關人員分析
  • 分析的前提條件與限制
  • 分析方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 科技與創新趨勢
  • 新興市場和高成長市場
  • 監管和政策環境
  • 感染疾病的影響及恢復前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商議價能力
    • 買方的議價能力
    • 替代產品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球疫苗研發與冷鏈物流市場：依價值鏈階段分類

  • 研究與開發
  • 臨床試驗
  • 製造和規模化
  • 配送和冷鏈物流
  • 最終用途/管理

第6章 全球疫苗研發與冷鏈物流市場：依疫苗類型分類

  • 藥效疫苗
  • 病毒載體疫苗
  • 蛋白質次單元疫苗
  • 去活化減毒活病毒疫苗

第7章 全球疫苗研發與冷鏈物流市場：依冷鏈組成部分分類

  • 冷藏保管。
  • 冷藏運輸
  • 包裝解決方案
  • 監控和追蹤系統

第8章：全球疫苗研發與冷鏈物流市場：依運輸方式分類

  • 空運
  • 道路運輸
  • 海上運輸

第9章：全球疫苗研發與冷鏈物流市場：依最終用戶分類

  • 製藥公司
  • 研究機構
  • 醫院和診所
  • 疫苗接種中心
  • 政府和公共衛生機構

第10章：全球疫苗研發與冷鏈物流市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 產業加值網路與供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 企業合併（M&A）
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Pfizer
  • BioNTech
  • Moderna
  • GSK
  • Sanofi
  • CureVac
  • Merck
  • Lonza
  • Samsung Biologics
  • Wuxi Biologics
  • Gennova Biopharmaceuticals
  • Arcturus Therapeutics
  • Thermo Fisher Scientific
  • Aldevron
  • UPS Healthcare
  • DHL Supply Chain
  • Kuehne+Nagel
  • Americold Logistics
Product Code: SMRC39750

According to Stratistics MRC, the Global Vaccine Development & Cold Chain Logistics Market is accounted for $18.7 billion in 2026 and is expected to reach $35.7 billion by 2034 growing at a CAGR of 8.4% during the forecast period. Vaccine development and cold chain logistics play a critical role in delivering safe and effective vaccines from research facilities to patients. Development covers discovery, laboratory studies, clinical trials, regulatory approval, manufacturing, and commercialization. Cold chain systems preserve vaccines within specified temperature ranges during storage and transportation, helping maintain their effectiveness. Modern refrigeration technologies, temperature sensors, monitoring devices, insulated packaging, and digital tracking solutions are strengthening distribution efficiency. Reliable cold chain networks are particularly important for expanding vaccination coverage in remote and underserved healthcare markets.

According to UNICEF, 2.787 billion vaccine doses were delivered to 99 countries in 2024, enough to reach about 45% of the world's children under five. This demonstrates the enormous scale of global vaccine procurement and distribution activity supporting demand for cold-chain logistics.

Market Dynamics:

Driver:

Growing global vaccination programs and immunization coverage

The expansion of immunization initiatives is strengthening demand across vaccine development and cold chain logistics. As national vaccination programs and international health efforts reach larger populations and wider geographic areas, the need for vaccine production, controlled storage, refrigerated transportation, and efficient distribution continues to increase. Broader immunization coverage also highlights the importance of dependable last-mile logistics in rural and underserved locations. This is encouraging greater investment in cold storage infrastructure, temperature-control technologies, insulated containers, monitoring equipment, and specialized transportation solutions for vaccine distribution.

Restraint:

High costs of temperature-controlled infrastructure

The substantial expense of establishing and maintaining temperature-controlled infrastructure can limit market expansion. Cold chain operations require specialized refrigeration equipment, freezers, refrigerated transportation, insulated packaging, monitoring technologies, backup electricity, and compliant storage facilities, creating significant investment requirements. Continuous energy use, maintenance, calibration, and equipment replacement add to operational costs. These financial pressures can be especially difficult for healthcare organizations and logistics companies operating in developing or geographically remote areas, potentially limiting cold chain expansion and reducing the efficiency of vaccine delivery.

Opportunity:

Expansion of vaccine access in emerging markets

Increasing vaccine availability in developing and underserved regions offers new growth opportunities for vaccine developers and cold chain logistics companies. Greater healthcare spending, immunization campaigns, and preventive healthcare programs are generating demand for reliable temperature-controlled storage and transportation. Businesses can capitalize by establishing regional refrigeration facilities, adopting solar-powered cold chain equipment, and providing insulated transportation and digital temperature-monitoring technologies. Improved last-mile delivery capabilities can help reach remote populations more effectively. Such investments can broaden logistics networks and facilitate wider access to vaccines across emerging healthcare markets.

Threat:

Supply chain disruptions and infrastructure vulnerabilities

Global vaccine supply chains remain vulnerable to disruptions that can affect cold storage and distribution operations. Extreme weather events, logistical delays, geopolitical instability, power shortages, equipment breakdowns, and weak infrastructure can interfere with temperature-controlled transportation. These challenges may result in delayed deliveries, product losses, and reduced vaccine availability, especially in vulnerable locations. Reliance on continuous electricity, specialized refrigeration, and coordinated logistics adds further operational exposure. Companies and healthcare systems can mitigate these threats through backup equipment, alternative transportation routes, contingency planning, and expanded regional storage facilities.

Covid-19 Impact:

The COVID-19 outbreak transformed vaccine development and cold chain logistics by rapidly expanding vaccine research, testing, production, and vaccination initiatives worldwide. The large-scale rollout generated substantial requirements for refrigerated storage and controlled transportation. However, travel restrictions, border closures, labor shortages, and infrastructure limitations created supply chain difficulties across several markets. Governments and healthcare providers subsequently increased investments in cold storage equipment, temperature monitoring, specialized packaging, and distribution systems. The crisis demonstrated the need for stronger cold chain resilience, digital visibility, emergency preparedness, and coordinated logistics operations.

The distribution & cold chain logistics segment is expected to be the largest during the forecast period

The distribution & cold chain logistics segment is expected to account for the largest market share during the forecast period because vaccines require controlled handling throughout their journey from production sites to administration locations. The segment covers refrigerated transportation, cold storage facilities, temperature-sensitive packaging, inventory management, monitoring technologies, and last-mile delivery. Operations require close coordination between pharmaceutical manufacturers, logistics companies, medical facilities, and immunization sites, creating an essential component of the overall vaccine supply chain worldwide.

The vaccination centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the vaccination centers segment is predicted to witness the highest growth rate as their importance in community-based immunization delivery continues to expand. Greater focus on convenient vaccination access, large-scale immunization initiatives, and decentralized healthcare services is strengthening their role within vaccine distribution networks. The adoption of digital inventory management and advanced temperature-control solutions is also improving their operations. These developments are enabling vaccination centers to support broader vaccine availability and more efficient community-level administration.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, benefiting from sophisticated healthcare systems, a strong pharmaceutical industry, and well-established vaccine distribution infrastructure. The region supports extensive activities involving vaccine research, production, refrigerated storage, transportation, and delivery. Major pharmaceutical manufacturers, medical organizations, vaccination facilities, and specialized logistics providers contribute to a comprehensive ecosystem that supports the region's prominent role in vaccine supply and distribution.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as vaccination initiatives, healthcare infrastructure, and regional vaccine production continue expanding. Increasing requirements for reliable storage, transportation, monitoring, and distribution are encouraging improvements throughout the supply chain. The introduction of additional vaccines is further increasing cold chain needs across the region. Investments by governments, international agencies, and healthcare organizations in logistics infrastructure, digital tracking, and temperature-controlled systems are strengthening vaccine distribution capabilities and supporting market expansion.

Key players in the market

Some of the key players in Vaccine Development & Cold Chain Logistics Market include Pfizer, BioNTech, Moderna, GSK, Sanofi, CureVac, Merck, Lonza, Samsung Biologics, Wuxi Biologics, Gennova Biopharmaceuticals, Arcturus Therapeutics, Thermo Fisher Scientific, Aldevron, UPS Healthcare, DHL Supply Chain, Kuehne + Nagel and Americold Logistics.

Key Developments:

In December 2025, Pfizer Inc. announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.

In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.

Value Chain Stages Covered:

  • Research & Development
  • Clinical Trials
  • Manufacturing & Scale-up
  • Distribution & Cold Chain Logistics
  • End-use Administration

Vaccine Types Covered:

  • mRNA Vaccines
  • Viral Vector Vaccines
  • Protein Subunit Vaccines
  • Inactivated & Live-attenuated Vaccines

Cold Chain Components Covered:

  • Refrigerated Storage
  • Refrigerated Transportation
  • Packaging Solutions
  • Monitoring & Tracking Systems

Mode of Transports Covered:

  • Air Freight
  • Road Transport
  • Sea Transport

End Users Covered:

  • Pharmaceutical Companies
  • Research Institutes
  • Hospitals & Clinics
  • Vaccination Centers
  • Government & Public Health Agencies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Vaccine Development & Cold Chain Logistics Market, By Value Chain Stage

  • 5.1 Research & Development
  • 5.2 Clinical Trials
  • 5.3 Manufacturing & Scale-up
  • 5.4 Distribution & Cold Chain Logistics
  • 5.5 End-use Administration

6 Global Vaccine Development & Cold Chain Logistics Market, By Vaccine Type

  • 6.1 mRNA Vaccines
  • 6.2 Viral Vector Vaccines
  • 6.3 Protein Subunit Vaccines
  • 6.4 Inactivated & Live-attenuated Vaccines

7 Global Vaccine Development & Cold Chain Logistics Market, By Cold Chain Component

  • 7.1 Refrigerated Storage
  • 7.2 Refrigerated Transportation
  • 7.3 Packaging Solutions
  • 7.4 Monitoring & Tracking Systems

8 Global Vaccine Development & Cold Chain Logistics Market, By Mode of Transport

  • 8.1 Air Freight
  • 8.2 Road Transport
  • 8.3 Sea Transport

9 Global Vaccine Development & Cold Chain Logistics Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Research Institutes
  • 9.3 Hospitals & Clinics
  • 9.4 Vaccination Centers
  • 9.5 Government & Public Health Agencies

10 Global Vaccine Development & Cold Chain Logistics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Pfizer
  • 13.2 BioNTech
  • 13.3 Moderna
  • 13.4 GSK
  • 13.5 Sanofi
  • 13.6 CureVac
  • 13.7 Merck
  • 13.8 Lonza
  • 13.9 Samsung Biologics
  • 13.10 Wuxi Biologics
  • 13.11 Gennova Biopharmaceuticals
  • 13.12 Arcturus Therapeutics
  • 13.13 Thermo Fisher Scientific
  • 13.14 Aldevron
  • 13.15 UPS Healthcare
  • 13.16 DHL Supply Chain
  • 13.17 Kuehne + Nagel
  • 13.18 Americold Logistics

List of Tables

  • Table 1 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Value Chain Stage (2023-2034) ($MN)
  • Table 3 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Research & Development (2023-2034) ($MN)
  • Table 4 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Clinical Trials (2023-2034) ($MN)
  • Table 5 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Manufacturing & Scale-up (2023-2034) ($MN)
  • Table 6 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Distribution & Cold Chain Logistics (2023-2034) ($MN)
  • Table 7 Global Vaccine Development & Cold Chain Logistics Market Outlook, By End-use Administration (2023-2034) ($MN)
  • Table 8 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Vaccine Type (2023-2034) ($MN)
  • Table 9 Global Vaccine Development & Cold Chain Logistics Market Outlook, By mRNA Vaccines (2023-2034) ($MN)
  • Table 10 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Viral Vector Vaccines (2023-2034) ($MN)
  • Table 11 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Protein Subunit Vaccines (2023-2034) ($MN)
  • Table 12 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Inactivated & Live-attenuated Vaccines (2023-2034) ($MN)
  • Table 13 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Cold Chain Component (2023-2034) ($MN)
  • Table 14 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Refrigerated Storage (2023-2034) ($MN)
  • Table 15 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Refrigerated Transportation (2023-2034) ($MN)
  • Table 16 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Packaging Solutions (2023-2034) ($MN)
  • Table 17 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Monitoring & Tracking Systems (2023-2034) ($MN)
  • Table 18 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Mode of Transport (2023-2034) ($MN)
  • Table 19 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Air Freight (2023-2034) ($MN)
  • Table 20 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Road Transport (2023-2034) ($MN)
  • Table 21 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Sea Transport (2023-2034) ($MN)
  • Table 22 Global Vaccine Development & Cold Chain Logistics Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 24 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 25 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 26 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Vaccination Centers (2023-2034) ($MN)
  • Table 27 Global Vaccine Development & Cold Chain Logistics Market Outlook, By Government & Public Health Agencies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.